close

Agreements

Date: 2011-01-05

Type of information: R&D agreement

Compound: transporting therapeutic proteins across the blood-brain barrier into the central nervous system

Company: to-BBB (The Netherlands) Synageva BioPharma (USA)

Therapeutic area: Rare diseases

Type agreement:

R&D

Action mechanism:

Disease:

Details:

* On  January 5th, 2011,  Synageva BioPharma Corp and to-BBB technologies BV, a Dutch drug brain delivery company, have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system (CNS). This research collaboration will be the basis for a development program for therapies for multiple such rare diseases, including lysosomal storage diseases.

Financial terms:

Latest news:

Is general: Yes